| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$1 ) |
| | 2025 | 2021 | PLEX PHARMACEUTICALS INC | 1770 CORPORATE CIR | PETALUMA | CA | 94954-6924 | SONOMA | USA | R44EY027236 | Advancing CAP4196 into in vivo Proof of Concept Translational Studies | 000 | 4 | NIH | 3/19/2025 | -$1 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2021 | PLEX PHARMACEUTICALS INC | 1770 CORPORATE CIR | PETALUMA | CA | 94954-6924 | SONOMA | USA | R43EY031609 | Re-purposing the small-molecule drug, tafamidis (CAP4349) for the non-surgical treatment of cataracts | 000 | 2 | NIH | 4/9/2024 | $0 |
| | 2024 | 2021 | PLEX PHARMACEUTICALS INC | 1770 CORPORATE CIR | PETALUMA | CA | 94954-6924 | SONOMA | USA | R43AI145617 | Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health Threats | 000 | 2 | NIH | 1/8/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | PLEX PHARMACEUTICALS, INC. | 6330 NANCY RIDGE DR STE 105 | SAN DIEGO | CA | 92121-3230 | SAN DIEGO | USA | R43AI145617 | Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health Threats | 000 | 2 | NIH | 11/21/2022 | $0 |
| | 2023 | 2021 | PLEX PHARMACEUTICALS, INC. | 6330 NANCY RIDGE DR STE 105 | SAN DIEGO | CA | 92121-3230 | SAN DIEGO | USA | R43EY031609 | Re-purposing the small-molecule drug, tafamidis (CAP4349) for the non-surgical treatment of cataracts | 000 | 2 | NIH | 2/27/2023 | $0 |
| | 2023 | 2021 | PLEX PHARMACEUTICALS, INC. | 6330 NANCY RIDGE DR STE 105 | SAN DIEGO | CA | 92121-3230 | SAN DIEGO | USA | R44EY027236 | Advancing CAP4196 into in vivo Proof of Concept Translational Studies | 000 | 4 | NIH | 2/27/2023 | $0 |
| | 2023 | 2021 | PLEX PHARMACEUTICALS, INC. | 6330 NANCY RIDGE DR STE 105 | SAN DIEGO | CA | 92121-3230 | SAN DIEGO | USA | R44EY027236 | Advancing CAP4196 into in vivo Proof of Concept Translational Studies | 001 | 4 | NIH | 3/16/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2021 | PLEX PHARMACEUTICALS, INC. | 6330 NANCY RIDGE DR STE 105 | SAN DIEGO | CA | 92121-3230 | SAN DIEGO | USA | R43EY031609 | Re-purposing the small-molecule drug, tafamidis (CAP4349) for the non-surgical treatment of cataracts | 000 | 2 | NIH | 11/19/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,098,281 ) |
| | 2021 | 2021 | PLEX PHARMACEUTICALS, INC. | 6330 NANCY RIDGE DR STE 105 | SAN DIEGO | CA | 92121-3230 | SAN DIEGO | USA | R43EY031609 | Re-purposing the small-molecule drug, tafamidis (CAP4349) for the non-surgical treatment of cataracts | 000 | 2 | NIH | 7/13/2021 | $149,295 |
| | 2021 | 2021 | PLEX PHARMACEUTICALS, INC. | 6330 NANCY RIDGE DR STE 105 | SAN DIEGO | CA | 92121-3230 | SAN DIEGO | USA | R44EY027236 | Advancing CAP4196 into in vivo Proof of Concept Translational Studies | 001 | 4 | NIH | 7/13/2021 | $648,986 |
| | 2021 | 2021 | PLEX PHARMACEUTICALS, INC. | 6330 NANCY RIDGE DR STE 105 | SAN DIEGO | CA | 92121-3230 | SAN DIEGO | USA | R43AI145617 | Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health Threats | 000 | 2 | NIH | 1/26/2021 | $300,000 |
| | 2021 | 2020 | PLEX PHARMACEUTICALS, INC. | 6330 NANCY RIDGE DR STE 105 | SAN DIEGO | CA | 92121-3230 | SAN DIEGO | USA | R44EY027236 | Advancing CAP4196 into in vivo Proof of Concept Translational Studies | 000 | 3 | NIH | 4/26/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,112,161 ) |
| | 2020 | 2020 | PLEX PHARMACEUTICALS, INC. | 6330 NANCY RIDGE DR STE 105 | SAN DIEGO | CA | 92121-3230 | SAN DIEGO | USA | R44EY027236 | Advancing CAP4196 into in vivo Proof of Concept Translational Studies | 000 | 3 | NIH | 6/26/2020 | $662,896 |
| | 2020 | 2020 | PLEX PHARMACEUTICALS, INC. | 6330 NANCY RIDGE DR STE 105 | SAN DIEGO | CA | 92121-3230 | SAN DIEGO | USA | R43AI145617 | Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health Threats | 000 | 1 | NIH | 1/17/2020 | $300,000 |
| | 2020 | 2020 | PLEX PHARMACEUTICALS, INC. | 6330 NANCY RIDGE DR STE 105 | SAN DIEGO | CA | 92121-3230 | SAN DIEGO | USA | R43EY031609 | Re-purposing the small-molecule drug, tafamidis (CAP4349) for the non-surgical treatment of cataracts | 000 | 1 | NIH | 6/25/2020 | $149,295 |
| | 2020 | 2017 | PLEX PHARMACEUTICALS, INC. | 6330 NANCY RIDGE DR STE 105 | SAN DIEGO | CA | 92121-3230 | SAN DIEGO | USA | R43EY027236 | Small molecule activators of alpha-crystallin for non-surgical treatment of cataracts | 000 | 2 | NIH | 1/8/2020 | -$30 |
|
| Issue Date FY: 2017 ( Subtotal = $136,733 ) |
| | 2017 | 2017 | CALASIA PHARMACEUTICALS, INC. | 6330 NANCY RIDGE DR STE 102 | SAN DIEGO | CA | 92121-3220 | SAN DIEGO | USA | R43EY027236 | Small molecule activators of alpha-crystallin for non-surgical treatment of cataracts | 000 | 2 | NIH | 8/14/2017 | $136,774 |
| | 2017 | 2015 | CALASIA PHARMACEUTICALS, INC. | 6330 NANCY RIDGE DR STE 102 | SAN DIEGO | CA | 92121-3220 | SAN DIEGO | USA | R43AI114084 | Development of Flavivirus Antivirals Targeting Dengue Virus and WNV Protease | 000 | 2 | NIH | 8/31/2017 | -$41 |
|
| Issue Date FY: 2016 ( Subtotal = $162,399 ) |
| | 2016 | 2016 | CALASIA PHARMACEUTICALS INC | 11494 SORRENTO VALLEY ROAD | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43EY027236 | Small molecule activators of alpha-crystallin for non-surgical treatment of cataracts | 000 | 1 | NIH | 8/25/2016 | $162,399 |
|
| Issue Date FY: 2015 ( Subtotal = $300,000 ) |
| | 2015 | 2015 | CALASIA PHARMACEUTICALS INC | 11494 SORRENTO VALLEY ROAD | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43AI114084 | Development of Flavivirus Antivirals Targeting Dengue Virus and WNV Protease | 000 | 2 | NIH | 4/10/2015 | $300,000 |
|
| Issue Date FY: 2014 ( Subtotal = $300,000 ) |
| | 2014 | 2014 | CALASIA PHARMACEUTICALS INC | 11494 SORRENTO VALLEY ROAD | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43AI114084 | Development of Flavivirus Antivirals Targeting Dengue Virus and WNV Protease | 000 | 1 | NIH | 5/5/2014 | $300,000 |
|
| Issue Date FY: 2011 ( Subtotal = $0 ) |
| | 2011 | 2010 | CALASIA PHARMACEUTICALS INC | 11494 SORRENTO VALLEY ROAD | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43DK088457 | DISCOVERY AND DEVELOPMENT OF NOVEL GLUCOSE DEPENDENT PARTIAL GLUCOKINASE ACTIVATO | 000 | 1 | NIH | 4/4/2011 | $0 |
|
| Issue Date FY: 2010 ( Subtotal = $480,998 ) |
| | 2010 | 2010 | CALASIA PHARMACEUTICALS INC | 11494 SORRENTO VALLEY ROAD | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43DK088457 | DISCOVERY AND DEVELOPMENT OF NOVEL GLUCOSE DEPENDENT PARTIAL GLUCOKINASE ACTIVATO | 000 | 1 | NIH | 4/5/2010 | $201,930 |
| | 2010 | 2010 | CALASIA PHARMACEUTICALS INC | 11494 SORRENTO VALLEY ROAD | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43GM090383 | SELECTIVE AND DUAL-ACTING HSP90 AND TRAP1 INHIBITORS | 000 | 1 | NIH | 9/10/2010 | $279,068 |
|
|
